论文部分内容阅读
目的:探讨对胎盘植入产妇在产后进行保守治疗的临床治疗效果和安全性。方法:通过对2009年-2012年来我院产科分娩时确诊胚胎植入的11例患者在产后使用米非司酮来保守治疗,经过对产妇阴道的出血状况和药物不良反应的临床观察,产妇的血β-HCG值变化和彩超判断宫内状况来分析本次治疗的效果和安全性。结果:在治疗的过程中,11例患者均没有出现子宫收缩乏力、感染和阴道大量流血等病症,2例患者出现轻微的胃肠不适和皮疹等不良反应,但停药治疗后均恢复正常,所有患者在治疗后血β-HCG均逐渐下降,血常规和肝肾功能均正常。结论:使用米非司酮来治疗植入性胎盘患者的临床疗效显著,而且副作用低,安全性高,整体治疗结果让人满意。
Objective: To investigate the clinical effect and safety of conservative treatment of placenta accreta after delivery. Methods: From 2009 to 2012, 11 patients with confirmed embryo implantation during obstetric delivery in our hospital were treated conservatively with mifepristone after delivery. After the clinical observation of vaginal bleeding and adverse drug reactions, Blood β-HCG changes and color Doppler ultrasound to determine intrauterine status to analyze the effect and safety of this treatment. Results: In the course of treatment, all the 11 patients showed no signs of uterine atony, infection and mass vaginal bleeding, 2 patients had mild gastrointestinal discomfort and skin rash and other adverse reactions, but returned to normal after stopping treatment, All patients in the treatment of blood β-HCG were gradually decreased, blood and liver and kidney function were normal. CONCLUSIONS: The clinical efficacy of mifepristone for the treatment of implanted placenta is significant, with low side effects, high safety and satisfactory overall treatment outcomes.